There are currently 41 active clinical trials seeking participants for Cognitive Decline research studies. The states with the highest number of trials for Cognitive Decline participants are Illinois, Michigan, Minnesota and Ohio.
Cognitive Screening Made Easy for PCPs - R33 Phase
NCT06162026
Recruiting
This project will facilitate early detection of cognitive decline in older adults through development and implementation of an automated risk assessment and cognitive screening tool for use in primary care. By providing an automated tool developed specifically to address the needs of PCPs, it will be easier to screen for cognitive impairment, increasing the number of older adults who are screened and thus identified and treated.
Gender:
All
Ages:
60 years and above
Trial Updated:
04/23/2024
Locations: Family Wellness Clinic, Austin, Texas
Conditions: Cognitive Impairment, Dementia, Mild, Cognitive Decline
Register for Updates
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)
NCT05637801
Recruiting
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's disease. Approximately 530 subjects will be randomized to 12 months of daily treatment with either Active or Sham Sensory Stimulation Systems. Efficacy will be measured using the Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) assessment and a combined statistical test (CST) of the ADCS-ADL and the Mini-Mental State E... Read More
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/22/2024
Locations: CCT Research - Gilbert Neurology Partners, Gilbert, Arizona +67 locations
Conditions: Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
Register for Updates
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients
NCT04337255
Recruiting
To test the effects of a 2- to 3-year intervention of the MIND diet versus usual post-stroke care on cognitive decline, the characteristic feature of dementia, and on brain biomarkers of Alzheimer's Disease (AD) and vascular disease in a Phase Ill randomized controlled trial of 500 patients hospitalized for acute ischemic stroke, aged 55 years or older, and without dementia who are discharged home following hospitalization.
Gender:
All
Ages:
55 years and above
Trial Updated:
04/10/2024
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Cognitive Decline, Dementia, Vascular, Alzheimer Disease, Dementia, Stroke
Register for Updates
Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)
NCT05277558
Recruiting
Investigators propose to study youth across the spectrum of body mass index (BMI) and dysglycemia. This approach will allow investigators to disentangle the relationship of key features of type 2 diabetes (T2D) risk (e.g. obesity) with intermediary physiologic changes (e.g. insulin resistance, inflammation, β-cell dysfunction and dysglycemia) that pose a risk for the brain. Investigators will determine which of these factors are most associated with differences in brain structure and function am... Read More
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
04/10/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri +1 locations
Conditions: Type2 Diabetes, Type 2 Diabetes Mellitus in Obese, Dysglycemia, Microvascular Complications, Brain Structure, Obesity, Childhood, Diabetes in Adolescence, Inflammation, Insulin Resistance, Overweight, Childhood, Cognitive Decline
Register for Updates
Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging
NCT03954899
Recruiting
The study will examine whether 5mg melatonin (over the counter, OTC) over a 9-month period improves Alzheimer's disease (AD) biomarkers and cognitive function in two groups of individuals: those with mild cognitive impairment (MCI+) and those who are not (MCI-). AD biomarkers will be measured from cerebrospinal fluid (CSF) obtained from lumbar punctures. Cognitive function will be evaluated with routine neuropsychological tests.
Gender:
All
Ages:
Between 56 years and 85 years
Trial Updated:
04/03/2024
Locations: University of Iowa Hospitals & Clinics, Iowa City, Iowa
Conditions: Mild Cognitive Impairment, Cognitive Decline, Healthy Aging
Register for Updates
Dopaminergic Dysfunction in Late-Life Depression
NCT04469959
Recruiting
Late-Life Depression (LLD), or depression in older adults, often presents with motivational deficits, deficits in performance in cognitive domains including processing speed and executive dysfunction, and mobility impairments. This triad of findings implicate dopaminergic dysfunction as a core pathophysiologic feature in depression, and may contribute to cognitive decline and motor disability. Normal aging results in brain-wide dopamine declines, decreased D1/D2 receptor density, and loss of dop... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
03/13/2024
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania +1 locations
Conditions: Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa, Gait Impairment
Register for Updates
The Impact of Goode Health Beverage on Markers of Physiological and Neurocognitive Health
NCT06245382
Recruiting
The overall research objective of this proposal is to determine the acute and chronic impact of daily supplementation of a Good Health beverage on indices of physiological and neurocognitive health.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
03/12/2024
Locations: UT Arlington - Science and Engineering Innovation and Research Building, Arlington, Texas +1 locations
Conditions: Cardiovascular Diseases, Hypertension, Cognitive Decline, Diet, Healthy
Register for Updates
A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses
NCT05877196
Recruiting
The goal of this clinical trial is to test 6 months of aerobic exercise in older adults who are 65 years or older and have mild cognitive impairment (MCI) or probable/possible mild Alzheimer's Disease. The main questions it aims to answer are: test the effects of aerobic exercise on aerobic fitness, white matter hyperintensity (WMH) volume, and patient-centered outcomes; identify the best exercise to improve aerobic fitness and reduce non-responses over 6 months; and examines the mechanisms of... Read More
Gender:
All
Ages:
65 years and above
Trial Updated:
02/09/2024
Locations: Arizona State University, Phoenix, Arizona
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Cognitive Impairment, Cognitive Decline, Memory Loss, Memory Impairment
Register for Updates
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
NCT05607732
Recruiting
Our study intends to offer 'real world' evidence of a viable, sustainable means to mobilize primary care via a comprehensive strategy for detecting cognitive impairment and dementias, advancing next steps for referral, and participating in the care planning and management of affected patients and caregivers. We will conduct a clinic-randomized, pragmatic trial testing the effectiveness and fidelity of our NIH Toolbox-derived paradigm to improve early detection and management of cognitive impairm... Read More
Gender:
All
Ages:
45 years and above
Trial Updated:
02/06/2024
Locations: Oak Street Health, Chicago, Illinois
Conditions: Dementia, Cognitive Impairment, Cognitive Decline, Alzheimer Disease
Register for Updates
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
NCT05741060
Recruiting
The ACE Trial, funded by the National Institute on Ageing/National Institutes of Health (NIH), is a multicenter clinical trial. The ACE Trial will determine if taking the dietary supplement Equol could slow the progression of stiffening of the arteries, small blood vessel disease in the brain and memory decline. Equol is a soy-based supplement that has plant estrogen-like compounds in it. Equol is a metabolite of soy isoflavone. Our studies in Japan and other studies suggest that Equol may slow... Read More
Gender:
All
Ages:
Between 65 years and 85 years
Trial Updated:
01/24/2024
Locations: Emory University, Atlanta, Georgia +2 locations
Conditions: Arterial Stiffness, White Matter Lesions, Cognitive Decline
Register for Updates
Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study
NCT05393388
Recruiting
We will conduct a Tau PET scan in cognitively normal older adults, enrolled in the Aging Brain Cohort Dedicated to Diversity Study (ABCD2-Tau) study at the University of Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC).Study duration will generally be a one-day study visit for PET imaging, but all subjects will be followed annually as part of their participation in the ABCD2 study. Findings from this study will likely provide insight into the mechanisms and distinction... Read More
Gender:
All
Ages:
65 years and above
Trial Updated:
01/04/2024
Locations: Hospital of the University of Pennsylvania - Penn Memory Center, Philadelphia, Pennsylvania
Conditions: Cognitive Decline, Alzheimer Disease
Register for Updates
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
NCT06025877
Recruiting
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia. MCI impacts 12-18% of people in the United States over age 60 years (Alzheimer's Association. Mild Cognitive Impairment (MCI) available at https://www.alz.org/alzheimers-dementia/what-is-dementia/related_conditions/mild-cognitive-impairment. Accessed August 16, 2022). MCI does not substantially interfere with daily activities, although complex... Read More
Gender:
All
Ages:
55 years and above
Trial Updated:
12/13/2023
Locations: UCSF Memory and Aging Center, San Francisco, California +6 locations
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Impairment, Memory Impairment
Register for Updates